Abstract Background Melanoma is the most malignant skin tumor and difficult to cure with alternative treatments of chemotherapy, biotherapy, immunotherapy. Our previous study showed that triptolide ( TP) exhibited powerful tumoricidal activity against melanoma. However, clinical potential TP plagued by its poor aqueous solubility, short half-life, biotoxicity. Therefore, developing an ideal vehicle efficiently load achieving targeted delivery melanoma a prospective approach for making full...

Capivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment remains uncertain. This study aimed to evaluate the capivasertib plus fulvestrant versus alone for cancer from perspectives healthcare payers in United States. Meanwhile, experimental analysis perspective China, incorporating specific assumptions, was also conducted study. A partitioned survival model...

Interstitial fibrosis is a typical feature of all progressive renal diseases. The process frequently coupled with the presence pro‑fibrotic factors and inflammation. Naringin dihydroflavone compound that has been previously reported to exhibit anti‑fibrotic effects in liver, where it prevents oxidative damage. In present study, rat model interstitial cell were established evaluate naringin on inflammatory proteins markers kidney rats NRK‑52E cells, elucidate role TGF‑β/Smad signaling pathway...

Abstract Purpose The KEYNOTE‐062 trial demonstrated the efficacy and safety of pembrolizumab for advanced gastric cancer (GC). current study evaluated cost‐effectiveness alone or in combination with chemotherapy versus GC from perspective United States China. And results will provide evidence data support more drug selection‐related decisions research future. Methods A partitioned survival approach three states was created treatment GC. were derived individual patient generated by a specific...

Objective: The EXTREME clinical trial revealed that cetuximab plus chemotherapy improved the overall survival time of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) versus alone. current study examined cost-effectiveness compared alone in HNSCC from perspective China. Materials Methods: A partitioned model was implemented for R/M patients. Survival information derived CHANGE-2 trial. designed as a ten-year horizon, 3-week cycle, 3% discount rate costs...

Abstract Objective Cemiplimab, a novel PD-1 inhibitor, exhibits significant antitumor activity against advanced non-small cell lung cancer (NSCLC). However, the cost-effectiveness of this drug for treatment remains unclear. This study aimed to assess cemiplimab plus chemotherapy compared NSCLC, from perspective United States payer. Methods A partitioned survival approach was developed project disease progression NSCLC. Overall (OS) and progression-free (PFS) data were obtained EMPOWER 3...

To compare the efficacy, safety, and cost-effectiveness of methotrexate (MTX) plus hydroxychloroquine (HCQ) vs MTX leflunomide (LEF) in established rheumatoid arthritis (RA) with inadequate response to monotherapy a real-world Chinese cohort.A prospective RA cohort (n=549) was screened eligible patients who had (disease activity score 28 joints using erythrocyte sedimentation rate, DAS28-ESR>3.2) initial subsequently received either MTX+HCQ or MTX+LEF. Propensity matching (PSM) applied...

Recently, the DESTINY-Breast04 trial revealed that significant benefits in both overall survival (OS) and progression-free (PFS) patients with HER2-low advanced or metastatic breast cancer treated trastuzumab deruxtecan (T-DXd) compared chemotherapy. The current study assessed cost-effectiveness of T-DXd from perspective United States payer.We developed a partitioned model to project disease course cancer. OS PFS data were derived trial. We extrapolate beyond follow-up time assess long-term...

Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). current study evaluated cost-effectiveness nab-paclitaxel TNBC from perspective Chinese health sector. Methods: A partitioned survival model was implemented patients with TNBC. data were derived trial. Direct costs and utility values collected Drug Bidding Database published literatures. primary analysis outcomes quality-adjusted...

Purpose: According to the IMvigor130 trial, adding atezolizumab platinum-based chemotherapy was effective in treatment of metastatic urothelial cancer (mUC). Based on perspective United States and China, current study evaluated cost-effectiveness plus for mUC patients first-line setting. Methods: A partitioned survival model adopted patients. The data were derived from trial. Direct cost values collected Centers Medicare Medicaid Services (CMS), Chinese Drug Bidding Database, published...

Spinal cord ischemia-reperfusion injury, a severe form of spinal damage, can lead to sensory and motor dysfunction. This injury often occurs after traumatic events, surgeries, or thoracoabdominal aortic surgeries. The unpredictable nature this condition, combined with limited treatment options, poses significant burden on patients, their families, society. leads reduced neuronal regenerative capacity complex pathological processes. In contrast, mitophagy is crucial for degrading damaged...

Assessments of patients' preferences can support in clinical decision-making regarding biologic therapies for psoriasis. Our objective was to investigate patient preference treatments patients with psoriasis China.From October 2020 January 2021, were recruited a survey that included demographic and disease-related questions, as well discrete choice experiment measure their therapy. A discrete-choice used which respondents selected based on benefits (ie, early onset efficacy, long-term...

The therapy of rheumatoid arthritis (RA) was advanced by biological agents, yet costly. This study aims to identify the effective threshold dose etanercept (ENT) and cost-effectiveness in methotrexate (MTX)-resistant RA real world.Eligible patients had an inadequate response (DAS28-ESR > 3.2) initial MTX monotherapy, subsequently received etanercept. cut-off value cumulative identified maintain remission < 2.6) at month 24 using restricted cubic splines. Remission rate, low disease activity...

Abstract Background: The therapy of rheumatoid arthritis (RA) was advanced by biological agents, yet costly. This study aims to identify the effective threshold dose etanercept (ENT) biosimilars and evaluate efficacy, safety cost-effectiveness in methotrexate (MTX)-resistant RA real world. Methods: Eligible patients had an inadequate response (DAS28-ESR＞3.2) initial MTX monotherapy, subsequently received biosimilar etanercept. cutoff value cumulative identified maintain remission...